Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HL036 in Healthy Korean Male Volunteers
NCT02717208Phase 1Completed
- Sponsor
- HanAll Biopharma
- Start
- Feb 2016
- Primary completion
- Jun 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tanfanercept in dry eye disease (DED) (2 cohorts), sponsored by HanAll Biopharma. Primary endpoint: Adverse Events at 1 week. Started Feb 2016; status: completed.
02
Drugs
tanfanercept
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT02717208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02717208.